Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 3/20 | 0.31 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966951 | 0.86 | HRH4 (0.32) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL966952 | 0.78 | HRH4 (0.33) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL963337 | 0.76 | HRH4 (0.32) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL27207006 | 0.72 | SCD (0.40) | CYP2C9ALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL27207432 | 0.70 | ADRB1 (0.39) | CYP2C9ALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL966950 | 0.65 | ALDH1A1 (0.36) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL963334 | 0.64 | ALDH1A1 (0.35) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL27207381 | 0.63 | SCD (0.43) | LMNAIRAK4 | |
| SCHEMBL6304381 | 0.62 | BAZ2A (0.39) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL27202056 | 0.62 | ACVR1 (0.41) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | PRXL2A, CUTA, MC1R | LMNA 176/4885CYP2C9 270/4885ATP6V1B2 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.